New Data at ASCO GU Show Power of Veracyte’s Decipher Tests to Improve Patient Care and Its GRID Tool to Advance Prostate and ...

The findings could lead to genetic tests that predict the likelihood of disease recurrence in breast cancer patients and ...

High prostate-specific antigen levels before High-Intensity Focused Ultrasound were linked to higher recurrence and treatment failure in intermediate-risk prostate cancer.

The Decipher Bladder Genomic Subtyping Classifier found that patients with luminal tumors may have less aggressive disease.

Guardant Health is overcoming skepticism with new cancer tests. Learn why GH stock is a buy, with strong growth and a shift ...

GRAIL, Inc. , a healthcare company whose mission is to detect cancer early when it can be cured, and Quest Diagnostics , a leading provider of diagnostic information services, today announced the ...

There could be new hope on for kidney cancer patients. Researchers announced early results of an anti-tumor vaccine for ...

Signatera uses circulating tumor DNA to detect and quantify cancer left in the body, identify recurrence earlier than standard-of-care tools, and help optimize treatment decisions. The test is ...

Bladder cancer is the second most common genitourinary malignancy after prostate cancer ... Urine cytology is a sensitive test for the detection of recurrence of high-grade, superficial and ...

Cancer misinformation spreads farther and faster than accurate information on social media, through public posts, by word of mouth, and private messages. This harmful content includes claims that are ...

The phase 3 trial AMPLIFY study plans to test the diagnostic performance of 64Cu-SAR-bisPSMA PET/CT imaging in approximately 220 patients with prostate cancer with biochemical recurrence. In this ...